Patricia Obermaier
ASGNAbout Patricia L. Obermaier
Independent director at ASGN since June 2024; former senior executive at Microsoft’s Global Health & Life Sciences division where she served as Chief Growth Officer and VP, Strategic Initiatives (2023–2024) and VP, U.S. Health and Life Sciences (2019–2023). Education: B.S. in Biology from MIT and MBA from the University of Virginia Darden School. Core credentials include scaling consulting businesses, strategy execution, and technology commercialization across healthcare and enterprise IT; she is classified as independent under NYSE standards as of March 19, 2025.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Microsoft | Chief Growth Officer & VP, Strategic Initiatives, Global Health Life Sciences | 2023–2024 | Led go-to-market and scaled commercial resources for a $12B division |
| Microsoft | VP, U.S. Health & Life Sciences | 2019–2023 | Drove growth initiatives and market capture in U.S. HLS |
| Resigility | Founder & CEO | 2015–2019 | Strategic advisory and information management services; business transformation focus |
| IQVIA | VP, GM and other roles | 2009–2015 | Commercial leadership in life sciences services |
| Unisys | Lead partner/Chief Strategy Officer of business units and other roles | 2001–2009 | Strategy and transformation across technology services |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Applied Information Sciences (private) | Director | Not disclosed | Mid-size commercial and government IT technology provider |
Board Governance
- Committee assignments: Strategy & Technology Committee member since June 2024; no chair roles disclosed. The Strategy & Technology Committee met four times in 2024 and oversees strategy, technology enablement, and cybersecurity/IT risk management.
- Independence: The Board determined all directors except the CEO are independent; Obermaier is independent per NYSE standards.
- Meetings and engagement: ASGN’s Board held six meetings in 2024; independent directors meet in executive session; all directors attended the 2024 Annual Meeting.
- Risk oversight: Cybersecurity and IT risk oversight flows through Strategy & Technology Committee with quarterly CISO reports; ERM program overseen by Audit Committee.
Fixed Compensation
| Component | Amount/Structure | As Applied to Obermaier (2024) |
|---|---|---|
| Annual cash retainer (Outside Directors) | $85,000 per year | Pro rated (joined June 2024): $49,451 fees earned in cash |
| Committee membership fees (non-chair) | Audit $12,000; Compensation $7,500; Nominating & Corporate Governance $5,000; Strategy & Technology $5,000 | Pro rated within cash fees; specific breakout not disclosed |
| Chair fees (if applicable) | Chair of Board $100,000; Audit Chair $18,000; Compensation Chair $17,500; Nominating & Corporate Governance Chair $15,000; Strategy & Technology Chair $15,000 | Not applicable (no chair role) |
| Meeting fees | Not disclosed | — |
| Other | Director education reimbursement up to $2,500 annually | Policy in place; individual usage not disclosed |
| Director Compensation (2024) | Cash Fees | Stock Awards (Grant-Date Fair Value) | All Other Compensation | Total |
|---|---|---|---|---|
| Patricia L. Obermaier | $49,451 | $184,983 | $40,549 (Board adviser fees prior to directorship) | $274,983 |
Performance Compensation
| Equity Grant Terms (Directors) | Details |
|---|---|
| Annual RSU grant value | ~$185,000 grant-date value for non-executive directors |
| Vesting schedule | One-half vests on grant date; remaining half vests on one-year anniversary |
| Obermaier grant | Granted upon nomination June 13, 2024; fair value per share $89.45; held 1,034 unvested shares as of Dec 31, 2024 |
| Performance metrics | None for directors (time-vesting RSUs; no PSUs/options disclosed) |
Other Directorships & Interlocks
- Current public company boards: None disclosed for Obermaier in ASGN’s proxy.
- Private boards: Director at Applied Information Sciences (commercial and government IT provider).
- Interlocks/related party exposure: None disclosed involving Obermaier; Audit Committee oversees related-party transactions process.
Expertise & Qualifications
- Skills matrix highlights: Consulting industry experience; government contract experience; technology/systems/cyber; talent management/compensation; marketing/sales; risk management; corporate governance.
- Recognitions: Multiple industry awards (Women in Technology STEM Leadership; Fierce Healthcare Women of Influence; NVTC Tech100; Washington Exec Top Health Care Execs to Watch).
- Education: MIT (B.S., Biology); University of Virginia Darden School (MBA).
Equity Ownership
| Metric | Value |
|---|---|
| Total beneficial ownership (Mar 31, 2025) | 1,709 shares; less than 1% of outstanding |
| Unvested RSUs (Dec 31, 2024) | 1,034 shares |
| Ownership guidelines (Directors) | 5× annual cash retainer ($425,000 requirement) |
| Compliance status | All directors/officers in compliance as of Mar 1, 2025 |
| Hedging/pledging | Prohibited for directors and executive officers |
Governance Assessment
-
Positive signals:
- Independence affirmed; assignment to Strategy & Technology Committee aligns with her technology and healthcare consulting background and strengthens cybersecurity/IT risk oversight.
- Director pay mix emphasizes equity (~$185k RSU annually), supporting alignment with shareholders; ownership guidelines enforced and in compliance.
- Board governance practices include independent Chair, regular executive sessions, ERM framework, and robust committee structures.
-
Watch items / potential red flags:
- Administrative Section 16(a) filing error on initial Form 3 omitted 200 shares at nomination; noted as an administrative error and corrected—minor, but monitor future compliance hygiene.
- Pre-director “All Other Compensation” of $40,549 reflects Board adviser fees in 2024 prior to joining the Board; independence subsequently affirmed, and Audit Committee oversees related-party processes, but investors may wish to monitor any ongoing advisory relationships for perceived conflicts.
-
Overall view:
- Governance quality appears solid with strong independence safeguards, cybersecurity oversight, and stock ownership requirements; compensation structure for directors is standard, equity-heavy, and time-vested (no options or performance metrics), which aligns but offers limited performance conditioning at the board level.